EYPT
EyePoint·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EYPT
Eyepoint Pharmaceuticals Inc.
A pharmaceutical company that focused on ophthalmic treatments
480 Pleasant Street, Watertown, MA 02472
--
EyePoint Pharmaceuticals Inc., became a Delaware corporation in March 2008. Its predecessor, pSivida Limited, was incorporated as an Australian company in Western Australia in December 2000. PSivida develops tiny, extended-release, drug-delivered products. The company's products for drug delivery are designed to control and stabilize drug delivery rates over months or years. PSivida is focused on leveraging its core technology platforms, Durasert and BioSilicon, to treat chronic diseases in the back of the eye. PSivida currently has three approved products and two major product candidates in development that represent successive generations of the Durasert technology platform. Three-quarters of pSivida's sustained-release devices for the treatment of retinal diseases are currently approved by the United States or the European Union (EU).
Earnings Call
Q1/2025
Estimate EPS-0.69
Actual EPS-0.65
Estimate Revenue8.84M
Actual Revenue24.45M
EyePoint Pharmaceuticals: Key Contradictions in Phase 3 Trial Timelines and FDA Interactions
May 07,2025 03:04
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.8
Actual EPS-0.85
Estimate Revenue6.16M
Actual Revenue5.30M
Contradictions Unveiled: Regulatory Strategies and Trial Timelines in Latest Biopharma Call
Aug 06,2025 04:21
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.77
Actual EPS-0.85
Estimate Revenue3.33M
Actual Revenue966.00K
EyePoint's Q3 2025: Contradictions Emerge on DME Trial Endpoints, Enrollment Timing, and Design
Nov 05,2025 02:51
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
EYPT has released its 2025 Q3 earnings. EPS was reported at -0.85, versus the expected -0.77, missing expectations. The chart below visualizes how EYPT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EYPT has released its 2025 Q3 earnings report, with revenue of 966.00K, reflecting a YoY change of -90.82%, and net profit of -59.73M, showing a YoY change of -103.44%. The Sankey diagram below clearly presents EYPT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
